| Date | Title | Description | Source |
| 12.03.2024 | Aileron Therapeutics Announces CEO Transition | - | globenewsw... |
| 31.10.2023 | Aileron Therapeutics Acquires Lung Therapeutics | Aileron Therapeutics, Inc. (NASDAQ: ALRN) acquired Lung Therapeutics, Inc., an Austin, Texas-based b... | finsmes.co... |
| 26.10.2022 | Aileron Therapeutics Presents Results from Phase 1 Study in ... | p53-mediated cell cycle arrest results demonstrate potential of ALRN-6924 to prevent chemotherapy-in... | globenewsw... |
| 30.09.2022 | Aileron Therapeutics Announces Oral Presentation of Non-Clin... | New ex vivo data demonstrates protection against cyclophosphamide-induced damage to hair follicles a... | globenewsw... |
| 22.09.2022 | Aileron Therapeutics to Present and Participate in a Firesid... | BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection on... | globenewsw... |
| 06.09.2022 | Aileron Therapeutics to Present at the H.C. Wainwright 24th ... | BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection on... | globenewsw... |
| 15.08.2022 | Aileron Therapeutics Reports Second Quarter 2022 Financial R... | Company continues to advance ALRN-6924 as a selective chemoprotective agent for all patients with p5... | globenewsw... |
| 01.08.2022 | Aileron Therapeutics Is Pleased to Outline Strategy to Stren... | Enhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity... | globenewsw... |
| 08.07.2022 | Aileron Therapeutics to Participate in Fireside Chat at the ... | BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection onc... | globenewsw... |
| 29.06.2022 | Aileron Therapeutics Announces Interim Data from Phase 1b Ch... | Patients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles o... | globenewsw... |
| 19.05.2022 | Aileron Therapeutics Announces First Patients Treated in Pha... | Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-in... | globenewsw... |
| 17.05.2022 | Aileron Therapeutics to Present at the H.C. Wainwright Globa... | BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection onco... | globenewsw... |
| 13.05.2022 | Aileron Therapeutics to Host Virtual KOL Investor Event on M... | BOSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection onco... | globenewsw... |
| 05.05.2022 | Aileron Therapeutics Reports First Quarter 2022 Financial Re... | On track to report interim results from Phase 1b clinical trial of ALRN-6924 in patients with advanc... | globenewsw... |
| 28.03.2022 | Aileron Therapeutics Reports Fourth Quarter and Full Year 20... | Several anticipated catalysts in 2022 aim to advance Aileron’s vision to bring chemoprotection again... | globenewsw... |
| 22.03.2022 | Aileron Therapeutics to Participate in Maxim Group 2022 Virt... | BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection on... | globenewsw... |
| 05.01.2022 | Aileron Therapeutics Provides Business Update and Outlines 2... | Plans to initiate Phase 1b clinical trial of ALRN-6924 in neoadjuvant breast cancer in 1H22; interim... | globenewsw... |
| 04.01.2022 | Aileron Therapeutics to Present at Upcoming Investor Confere... | BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection onc... | globenewsw... |
| 12.11.2021 | Aileron Therapeutics Reports Third Quarter 2021 Financial Re... | Continues to progress Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in pa... | globenewsw... |
| 07.10.2021 | Aileron Therapeutics Presents Data at AACR-NCI-EORTC Interna... | -- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agent
for patient... | globenewsw... |
| 30.09.2021 | Aileron Therapeutics : Announces Presentation of New Preclin... | BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection on... | marketscre... |
| 11.05.2021 | AILERON THERAPEUTICS, INC.
Aileron Therapeutics Reports Fir... | Progressing ALRN-6924: on track to initiate Phase 1b randomized placebo-controlled trial in patients... | marketscre... |
| 24.03.2021 | AILERON THERAPEUTICS, INC.
Aileron Therapeutics Reports Fou... | 2020 marked a year of successful evolution to a chemoprotection oncology company focused on fundamen... | marketscre... |
| 04.03.2021 | Aileron Therapeutics to Present at 2021 H.C. Wainwright Glob... | WATERTOWN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announ... | globenewsw... |
| 02.03.2021 | Aileron Therapeutics Announces Enrollment Expansion for Upco... | -- Placebo-controlled trial anticipated to enroll 60 patients with advanced p53-mutated NSCLC underg... | globenewsw... |
| 20.06.2017 | Term Sheet — Tuesday, June 20 | “I GOT A FEELING I’M OFF SCRIPT”
NEW MONEY + NEW PRODUCT: Managed by Q, a New York City-based on-dem... | fortune.co... |
| 05.06.2017 | Aileron Therapeutics files for a $69M IPO as new offeri... | Joseph Yanchik, Aerilon
Aileron Therapeutics has set out to raise $69 million in the latest bi... | endpts.com... |
| 31.10.2014 | Funding Roundup: Which biotech, medtech and healthIT startup... | $33 million in equity raised, closing out a $48 million Series E round
The funding will bring Ailero... | medcitynew... |
| 30.10.2014 | Aileron Therapeutics closes $33M to launch clinical trials f... | Three new investors are involved here – AJU IB Investment Co., and two undisclosed private investmen... | medcitynew... |
| 29.10.2014 | Aileron Therapeutics Secures Additional $33M in Series E Fin... | Aileron Therapeutics, Inc., a Cambridge, MA-based clinical stage biopharmaceutical company that is d... | finsmes.co... |
| 29.10.2014 | Aileron Therapeutics Secures $33M in Series E |
CAMBRIDGE, MA, Clinical stage biopharmaceutical company that is developing first-in-class therapeu... | vcnewsdail... |
| 18.11.2013 | Aileron Therapeutics Secures $30M in Series E |
CAMBRIDGE, MA, Clinical stage biopharmaceutical company that is developing first-in-class therapeu... | vcnewsdail... |
| 18.11.2013 | Big Pharma venture arms bet $30M more on Aileron’s ‘stapled ... | The company’s lead candidate, ALRN-5281, is a long-acting growth-hormone-releasing factor agonist th... | medcitynew... |
| 18.11.2013 | Aileron Therapeutics Secures $30M in Series E Equity Financi... | Aileron Therapeutics, a Cambridge, MA-based clinical stage biopharmaceutical company, secured $30m i... | finsmes.co... |
| 14.01.2013 | Biopharma adds $12M to advance “stapled peptide” technology ... | Attempts to modulate intracellular processes have historically failed, the company says, because pep... | medcitynew... |
| 14.01.2013 | Aileron Therapeutics Raises $12M in Series D Financing | Aileron Therapeutics, Inc., a Cambridge, Massachusetts-based biopharmaceutical company developing an... | finsmes.co... |
| 14.01.2013 | Aileron Therapeutics Secures $12M Series D |
CAMBRIDGE, MA, Aileron Therapeutics, Inc. today announced that it secured the second tranche in it... | vcnewsdail... |
| 07.07.2009 | New life-science fund launches, Midwest investment on the ho... | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Healt... | medcitynew... |
| 15.04.2008 | Aileron Raises $10 Million | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Cambridge-based biopharmaceutical c... | xconomy.co... |
| 07.06.2007 | Aileron Therapeutics pulls in $7M for peptide therapies | Aileron Therapeutics, a Cambridge, Mass., developer of peptide-based drugs for cancer, raised $7 mil... | venturebea... |
| - | Biopharma adds $12M to advance “stapled peptide” technology ... | Biopharmaceutical company Aileron Therapeutics Inc. is ready to advance what it says is a new class ... | medcitynew... |
| - | Big Pharma venture arms bet $30M more on Aileron’s ‘stapled ... | Just 10 months after closing the second tranche of a $42 million financing round, a biopharma develo... | medcitynew... |
| - | Funding Roundup: Which biotech, medtech and healthIT startup... | Each week, many millions are invested into life sciences startups. There are so many that often, the... | medcitynew... |
| - | Aileron Therapeutics closes $33M to launch clinical trials f... | A new class of cancer drugs called “stapled peptides” has attracted a nice chunk of venture dollars.... | medcitynew... |
| - | New life-science fund launches, Midwest investment on the ho... | BOSTON, Massachusetts — A new health-care venture fund will invest in sectors ranging from informati... | medcitynew... |
